Takeda Adds Celiac Disease Candidate To GI Efforts
Phase II Study Shows Antigen-Specific Immune Tolerance Is Possible In Autoimmune Diseases
Takeda has exercised an option on partner Cour Pharmaceutical’s first-in-class lead product, after a positive Phase IIa study showed, for the first time, it was possible to induce specific immune tolerance to a foreign antigen in an autoimmune disease.
